Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced FibrosisJuly 25, 2014 | Press Release
Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic MelanomaJuly 22, 2014 | Press Release
July 9, 2014 | Press Release
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With FibrosisJune 23, 2014 | Press Release
Click here to view a presentation with findings from cohort 2 of a phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis.
View a New York Times article highlighting Galectin Therapeutics’ role in the fight against fatty liver diseaseJune 16, 2014 | News Article
May 21, 2014 | Webcast
May 14, 2014 | Presentation